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Abstract
AIM: To determine hepatitis C virus (HCV) seropreva-
lence and its genotypes, and to identify the factors as-
sociated with HCV infection. 
METHODS: This cross-sectional study, conducted in two 
prisons (one male and one female) in the State of Ser-
gipe, Brazil, comprised 422 subjects. All of the prisoners 
underwent a rapid test for the detection of HCV antibod-
ies. Patients with a positive result were tested for anti-
HCV by enzyme linked immunosorbent assay and for HCV 
RNA by qualitative polymerase chain reaction (PCR). The 
virus genotype was defined in every serum sample that 
presented positive for PCR-HCV. In order to determine 
the factors independently associated with positive serol-
ogy for HCV, multivariate logistic regression was used.
RESULTS: HCV seroprevalence was 3.1%. Of the 13 
subjects with positive anti-HCV, 11 had viremia con-
firmed by PCR. Of these, 90.9% had genotype 1. A total 
of 43 (10.2%) were injecting drug users, and HCV se-
roprevalence in this subgroup was 20.6%. The variable 
most strongly associated with positive serology for HCV 
was use of injecting drugs [odds ratio (OR), 23.3; 95% 
confidence interval (CI), 6.0-90.8]. Age over 30 years 
(OR, 5.5; 95%CI, 1.1-29.2), history of syphilis (OR, 9.8; 
95%CI, 1.7-55.2) and history of household contact with 
HCV positive individual (OR, 14.1; 95%CI, 2.3-85.4) 
were also independently associated with HCV infection.
CONCLUSION: Most of the HCV transmissions result 
from parenteral exposure. However, there is evidence 
to suggest a role for sex and household contact with 
an infected subject in virus transmission. 
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Hepatitis C virus (HCV) is one of  the main causes not 
only of  chronic viral hepatitis, but also of  cirrhosis and 
end-stage liver disease in the world[1]. Hepatitis C, given its 
treatment costs, high morbidity and mortality, generates 
a significant burden in healthcare systems. According to 
the World Health Organization, there are over 170 million 
people with chronic hepatitis C and approximately 3 to 4 
million new cases each year[2].
HCV seroprevalence in the general population has 
wide geographical variation. Studies performed in Bra-
zil have shown an anti-HCV prevalence of  5.9% in the 
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Amazon region, 0.9% in the State of  Rio de Janeiro and 
0.34% in the State of  Santa Catarina[3].
There are six HCV genotypes, with several subtypes. 
For each genotype, there is a different pattern of  treat-
ment response and, consequently, a distinct therapeutic 
approach[4,5]. There is a wide geographical variation when 
it comes to genotype distribution, so that genotypes 1, 2 
and 3 are more frequent in Europe, the USA and Japan; 
genotype 4 in central Africa, Egypt and the Middle East; 
genotype 5 in South Africa; and genotype 6 in Asia. Brazil 
in general has a higher prevalence of  genotype 1, followed 
by genotype 3[6]. 
Most HCV transmissions are due to parenteral expo-
sure. It has been estimated that HCV is 10 times more 
infectious than HIV, per unit of  blood, requiring less ex-
posure to reach high prevalence[1]. Other routes have been 
described, such as sexual and vertical transmission, but 
these are less common than the parenteral one. Risk fac-
tors already proposed include use of  injecting drugs (ID), 
tattoos, occupational blood exposure and hemodialysis[4,5]. 
It is important to highlight that HCV prevalence is higher 
in certain groups, such as prisoners[4]. Although these sub-
jects represent only 0.8% of  the American population, ap-
proximately 39% of  the cases of  chronic HCV infection 
have a history of  imprisonment[7]. There are several inter-
national studies which determined hepatitis C prevalence 
in prisons, but studies in Latin America are scarce. 
The following factors are related to higher prevalence 
of  HCV in prisoners: duration of  incarceration, use of  
ID, adverse socioeconomic situation and poor health care. 
Therefore, there is a potential public health issue, since 
the prison system works as a concentrator of  hepatitis C 
subjects and a dissemination center of  this infection. Risk 
behavior may precede imprisonment and continue after-
wards[8,9].
A large number of  HCV carriers are asymptomatic 
and remain undiagnosed for a long time, resulting in fur-
ther complications, such as liver cirrhosis, liver failure and 
hepatocellular carcinoma. These asymptomatic patients 
also represent a natural reservoir of  the disease, and a 
source of  dissemination[2].
Prisons in the State of  Sergipe, Brazil, do not currently 
screen for HCV and there are no statistics concerning 
HCV status of  the prisoners incidentally diagnosed. Given 
the regional variation of  HCV prevalence among prison-
ers, the lack of  data in Sergipe and its importance in order 
to implement effective strategies to prevent HCV trans-
mission, we conducted a study of  the prevalence of  HCV 
infection among prisoners, as well as HCV genotypes in 
viremic subjects, and factors associated with positive se-
rology for HCV.
MATERIALS AND METHODS
Study population
This was a cross-sectional study performed in two prisons 
(one male and one female) in the State of  Sergipe, Brazil. 
The study was conducted in the male prison in September 
2009 and in the female one in February 2010. Subjects eli-
gible for this study included all prisoners who agreed and 
signed the consent form.
Data collection
Structured and individual interviews were privately con-
ducted. Before the interview, it was explained that any col-
lected information would be kept confidential. Subjects’ 
names were not collected. Each questionnaire received a 
code number, in order to allow further connection to its 
respective blood sample, and was formed by closed ques-
tions, including sociodemographic characteristics and risk 
behaviors, such as the ones involving drug use and sexual 
practices, before and during the imprisonment.
Blood sample collection
After the interviews, the subjects underwent a rapid test 
for the detection of  HCV antibodies (kit HCV Rapid Test 
Bioeasy). Peripheral blood from those with a positive result 
in the rapid test was collected by a finger prick with a single 
use lancet. Then, six blood spots (two to confirm serology 
and four for molecular biology) were blotted onto high-
quality filter paper (Schleicher & Scheull 903). For each 
circle, approximately three drops of  blood were used. Af-
terwards, filter paper was left to dry at room temperature 
for 30 min or until the blood spot was completely dry. The 
material was kept in aluminum envelopes, along with a bag 
containing silica gel, and posted to Genoma Center. Only 
patients with positive anti-HCV had their results confirmed 
by qualitative polymerase chain reaction (PCR). Those with 
positive qualitative PCR had the HCV genotype determined. 
Statistical analysis
Continuous variables are reported as mean ± SD, and 
analyzed using the Mann-Whitney U test. Categorical 
variables are presented as percentages and analyzed us-
ing Chi-square (χ2) or Fisher’s exact tests. P < 0.05 were 
considered to be statistically significant. In order to iden-
tify parameters independently associated with positive 
serology for anti-HCV, a logistic regression model was 
determined. Variables with P < 0.1 in univariate analysis 
were included in the multivariate analysis. Before indicat-
ing which variables would be inserted in the initial model, 
multicollinearity issues were solved. Backward selection of  
variables was performed, with entry and retention set at a 
significance level of  0.05. The discrimination capability of  
the final model was evaluated through the area under the 
ROC curve (AUC), and the goodness-of-fit of  the logistic 
model was verified by the Hosmer-Lemeshow test (P > 
0.05). Variables that continued in the model were tested 
for possible interaction among them. Each interaction 
(between two variables) was individually tested and then 
added to the final model if  they showed statistical signifi-
cance. Statistical analyses were performed using the Statis-
tical Package for the Social Sciences, version 17 (Chicago, 
IL, USA).
This study was approved by the Research Ethics Com-
mittee of  the Federal University of  Sergipe in April 2009 
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(N° CAAE 0038.0.107.000-09). Prison authorities did not 
have access to any questionnaires or blood samples.
RESULTS
Prevalence and genotypes 
Of 382 men, 303 (79%) agreed to participate in the research, 
and of  137 women, 119 (87%) participated. All included 
subjects underwent the rapid test for the detection of  anti-
bodies to HCV, but one of  the subjects with a positive result 
for this test did not provide a blood sample for qualitative 
PCR. HCV seroprevalence was 3.1%. From the 13 subjects 
with positive anti-HCV, eleven had confirmed viremia by 
PCR. Of  these, 10 (90.9%) had genotype 1 (Table 1). 
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Table 1  Characteristics of prisoners with positive serology 
for hepatitis C virus in Sergipe, Brazil
n  (total = 131) %
Viremia (RNA) 11 84.6
Genotype
   1a   6 54.5
   1b   1   9.1
   1   3 27.3
   3   1   9.1
1One patient refused to provide a blood sample for polymerase chain 
reaction.
Table 2  Characteristics of 422 prisoners in Sergipe, Brazil
n  (total = 422) %
Gender
   Male 303 71.8
   Female 119 28.2
Age (yr)
   Mean (SD)              32.7 (8.8) 21.1
   ≤ 25   89 28.4
   25-30 120 19.4
   30-35   82 14.5
   35-40   61 16.6
   > 40   70
Education level
   Uneducated   45 10.7
   Less than high school 312 73.9
   High school or more   65 15.4
Religion
   Catholic 238 56.4
   Protestant   86 20.4
   Other   98 23.2
Race
   White 141 33.5
   Black 106 25.2
   Multiracial 160 38.0
   Other   14   3.3
Marital status
   Single 167 39.6
   Married 117 27.7
   Widowed   15   3.6
   Stable union 111 26.3
   Divorced   12   2.8
HCV seropositivity   13   3.1
HCV: Hepatitis C virus. 
Subject characteristics 
The mean age of  the subjects was 32.7 (± 8.8) years, and 
the most frequent age group was 25-30 years (28.4%). A 
total of  303 (72%) were men (recruited in the State Peni-
tentiary of  Areia Branca); and 119 (28%) were women 
(recruited in the Female Penitentiary of  Sergipe). Seventy-
two (60.5%) women and 39 (12.8%) men had drug deal-
ing or drug use as the reason for imprisonment. Many of  
the subjects were multiracial (38%) and single (39.6%). 
More than half  of  the population declared themselves as 
Catholics (56.4%) (Table 2).
Sexual practices and drug use
A total of  150 (35.5%) subjects reported previous sexu-
ally transmitted disease (STD), of  which gonorrhea was 
the most frequently declared. Two hundred and forty-
seven (58.5%) participants affirmed that they had paid 
or been paid for sex, and 109 (25.8%) rarely or never 
used condoms. Regarding drug use, 311 (73.7%) subjects 
had used illegal drugs, while 10.2% stated that they had 
used ID. Among ID users (IDU) (n = 43), 32.6% shared 
needles and syringes or other injecting equipment, 7% 
started injecting in prison and 11.6% continued injecting 
at the time of  the interview. HCV seroprevalence among 
IDU was 20.6% (Table 3). 
Univariate analysis 
As shown in Tables 4 and 5, we studied the association 
between serologic HCV status and sexual practices, drug 
use, sociodemographic and behavioral characteristics. 
Positive serology for HCV was significantly associated 
with the following characteristics: previous imprisonment; 
household contact with a HCV carrier; history of  tattoo-
ing, though there was no significance considering only tat-
tooing inside prison; previous syphilis; and use of  illegal 
drugs, including inhaled cocaine, marijuana and ID. How-
ever, use of  crack was not associated with HCV infection. 
Moreover, those with positive anti-HCV presented sig-
nificantly higher mean age, higher mean CAGE score and 
higher mean duration of  use of  inhaled cocaine, marijua-
na and ID. There was no significant association between 
HCV and marital status (data not shown), gender, ethnic-
ity, religion and sexual orientation. Rarely or never having 
Table 3  Characteristics of injecting drug users in prisoners in 
Sergipe, Brazil
n  (total = 43) %
Drug
   Cocaine 21 48.8
   Heroine   2   4.7
   Benzydamine 12 27.9
   Other 11 25.6
Duration of use (mean in years)                5.05 (5.7)
Use in the last 2 mo   5 11.6
Started to use during imprisonment   3   7.0
Uses inside the prison   5 11.6
Needle sharing 14 32.6
Anti-HCV (+)   9 20.9
HCV: Hepatitis C virus.
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used a condom, and a history of  paying or being paid for 
sex were not associated with a higher HCV seropreva-
lence. An association was not observed between STD and 
HCV, except for syphilis. Regarding partner characteris-
tics, the only variable that was significantly associated with 
HCV was a positive anti-HCV partner. Both groups (posi-
tive and negative anti-HCV) had similar mean duration of  
imprisonment, mean number of  sexual partners in the last 
year, mean age at the time of  the first sexual intercourse, 
mean family income and average years of  education. 
Multivariate analysis 
Multivariate logistic regression was performed using HCV 
status as the dependent variable. Among variables that 
presented collinearity issues (data not shown), the ones 
with greater clinical impact were chosen. Continuous 
variables were turned into dichotomous ones, using the 
receiver operating characteristic (ROC) curve to choose 
the cut-off  point that presented the best discrimination 
capability. Table 6 shows the variables independently as-
sociated with positive serology for HCV, and the strongest 
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Table 4  Socio-demographic and behavioral characteristics of 422 prisoners by serologic hepatitis C virus status, Sergipe, Brazil
Variable HCV (-) HCV (+) P -value
Gender (male)         295 (72.1%)             8 (61.5%)    0.531
Mean age (yr) 32.56 (8.8) 36.77 (6.4)    0.019
Ethnicity (white)         137 (33.6%)             4 (30.8%)    0.833
Christian religion         314 (76.8%)           10 (76.9%)    0.990
Family income (R$)       777 (1205)     684 (472)    0.923
Years of schooling (mean)     6.5 (5.4)     6.4 (2.9)    0.565
Mean incarcerated time (mo)  43.5 (40)  30.6 (30)    0.253
Previous imprisonment         139 (34.0%)           11 (84.6%) < 0.001
History of alcohol use         298 (73.0%)              10 (73.9.0%)    0.756
  CAGE (mean)   1.00 (1.2)   1.69 (1.2)    0.033
Household contact with HCV carrier         17 (4.2%)             4 (30.8%)    0.002
  History of tattooing         244 (59.7%)          13 (100%)    0.003
Tattooing inside prison         110 (27.0%)             6 (46.2%)    0.202
History of piercing         39 (9.5%) -    0.620
Previous blood transfusion         39 (9.5%) -    0.620
Previously shared razors, toothbrushes, nail trimmers or scissors         241 (58.9%)             8 (61.5%)    0.850
Getting wounded by a sharp weapon in a struggle         129 (31.5%)             3 (23.1%)    0.762
Total         409 (96.9%)         13 (3.1%)
HCV: Hepatitis C virus; CAGE: Cut down, Annoyed by criticism, Guilty e Eye-opener.
Table 5 Sexual practices and drug use of 422 prisoners by serologic hepatitis C virus status, Sergipe, Brazil 
Variable HCV (-) HCV (+) P -value
Never or rarely used condom         103 (25.3%)              6 (46.2%)     0.109
Sexual orientation (Heterosexual)         315 (77.2%)           13 (100%)     0.081
Number of partners in the last year (mean)   2.44 (8.1)   2.54 (5.3)     0.594
Age at first sexual intercourse (mean in years) 14.54 (2.3) 15.00 (1.7)     0.456
Sexually transmitted diseases         144 (35.2%)              6 (46.2%)     0.557
  History of genital herpes           6 (1.5%)            1 (7.7%)     0.198
  History of syphilis         17 (4.2%)              3 (23.1%)     0.019
  History of gonorrhea         109 (26.7%)              2 (15.4%)     0.528
Partner
   HCV (+)           4 (1.0%)              2 (15.4%)     0.012
   Illegal drug user         223 (54.5%)            10 (76.9%)     0.110
   Injecting drug user         24 (5.9%)            1 (7.7%)     0.553
   Previous imprisonment         124 (30.3%)              5 (38.5%)     0.548
Ever paid or been paid for sex         242 (59.2%)              5 (38.5%)     0.136
History of illegal drug use         298 (72.9%)           13 (100%)     0.025
  Inhaled cocaine         194 (47.4%)            11 (84.6%)     0.008
  Duration of inhaled cocaine (mean in mo)     107.6 (273.1)      86.1 (80.3)     0.006
  Marijuana         277 (67.7%)           13 (100%)     0.012
  Duration of marijuana use (mean in mo)     129.5 (220.5)      198.5 (101.4)     0.002
  Crack         129 (31.5%)              5 (38.5%)     0.561
  Duration of crack use (mean in mo)       77.9 (254.1)      162.0 (371.9)     0.369
  History of injecting drug use         34 (8.3%)              9 (69.2%) < 0.001
  Duration of injecting drug use (mean in mo)       26.1 (148.0)      261.2 (445.7) < 0.001
  Use of injecting drugs inside prison           5 (1.2%) -     0.855
  Ever shared needles and syringes or other injecting equipment         11 (2.7%)              3 (23.1%)     0.007
Total         409 (96.9%)          13 (3.1%)
HCV: Hepatitis C virus.
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association verified was between positive serology for 
HCV and use of  ID (OR, 23.3; 95% confidence interval 
(CI), 6.0-90.8). The chance of  presenting with positive an-
ti-HCV was 14 times higher among subjects that had lived 
with an HCV carrier compared with those without this 
history, even after adjusting for other variables, such as use 
of  ID. Age over 30 years and previous syphilis were also 
independently associated with positive serology for HCV. 
None of  the tested interactions was statistically significant 
(data not shown). The Hosmer-Lemeshow test had P = 
0.420, so the final model was considered to be adequate. 
Moreover, the area under the ROC curve was 0.90 (95%CI, 
0.81-0.99; P < 0.001), and the discrimination capability of  
the final model was considered to be good (Figure 1).
DISCUSSION
To our knowledge, this is the first study to determine HCV 
seroprevalence, and factors associated with this infection 
in inmates in Northeastern Brazil. HCV seroprevalence 
observed in this research was 3.1%, which is higher than 
that found in the general population (1.14%)[4]. Neverthe-
less, this percentage is below expectation, especially if  we 
consider the following aspects: the prevalence among pris-
oners described in other regions of  Brazil or even in other 
countries; the absence of  damage control programs in the 
evaluated prisons; and higher prevalence is expected in 
an already imprisoned population[10]. In Brazil, the studies 
conducted by Guimarães et al[5], Burattini et al[8] and Coelho 
et al[11] verified positive serology for HCV in 41%, 34% 
and 9% of  inmates, respectively. Catalan-Soares et al[12], 
in a study involving 63 prisoners, observed lower HCV 
seroprevalence (6.3%), but it was still twice that found in 
the present study. Moreover, Strazza et al[9], in a study in 
a Brazilian female prison, found an HCV seroprevalence 
of  16.2%. In the USA, in an incarcerated population, 
16%-41% presented serological evidence of  HCV infec-
tion, and approximately 12%-35% had chronic hepatitis 
C[7]. Experiences in Spain, England and France reported a 
prevalence of  48%, 30% and 30%, respectively[13].
It is important to point out that, depending on the stud-
ied region, even inside one country, HCV seroprevalence 
presents a wide variation. HCV seroprevalence seems to in-
crease along with the proportion of  IDU. Vescio et al[10], in a 
meta-analysis, concluded that the most important source of  
heterogeneity among studies is the different proportion of  
IDU in each population. In addition, according to the same 
study, HCV seroprevalence among IDU also has an impor-
tant influence on this heterogeneity. In our research, 10.2% 
of  the inmates declared that they had already used ID. This 
proportion varies from 3% to 69% throughout the world[10]. 
Perhaps the explanation for the proportion of  IDU not be-
ing as high as expected in our population is linked to the low 
percentage of  imprisonments motivated by drug dealing or 
drug use, and also to other social and cultural characteristics 
not assessed in the present investigation.
It has been reported that HCV-RNA may be detected 
in 40%-90% of  subjects with positive anti-HCV[2]. In our 
population, there was a high proportion of  positive HCV-
RNA-84.6% of  the inmates with positive anti-HCV-that is, 
subjects capable of  infecting others. This information cor-
roborates the hypothesis that prisoners are important car-
riers of  HCV and a potential source of  transmission[7,13], 
especially when many of  them will return to society.
Genotyping of  hepatitis C provides not only epide-
miological data, but also information from the perspective 
of  the therapeutic response. Treatment offers better re-
sults for genotypes 2 and 3[14]. Genotyping was performed 
in all 11 cases in which HCV-RNA was detected. We only 
identified genotypes 1 and 3, and genotype 1 was the 
most frequent (90.9%). Other studies also showed geno-
type 1 as the most frequent[14-18], but always with a higher 
frequency of  genotype 3 when compared with that in the 
present study. 
There was no significant difference in HCV seropreva-
lence with respect to gender. Previous results in the medi-
cal literature are conflicting, in spite of  one meta-analysis 
demonstrating a discreet predominance of  positive anti-
HCV among women[10]. However, this meta-analysis did 
not consider confounding variables that could be respon-
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Table 6  Multivariate logistic regression of characteristics associated with positive serology for anti-hepatitis C virus
Characteristic Crude odds ratio Adjusted odds ratio 95%CI P -value
Injecting drug user 24.8 23.3 6.0-90.8   0.0000
History of household contact with HCV carrier 10.2 14.1 2.3-85.4 0.004
Previous syphilis   6.9   9.8 1.7-55.2 0.009
Age > 30 yr   5.6   5.5 1.1-29.2 0.043
Hosmer-Lemeshow test (P = 0.420). HCV: Hepatitis C virus; CI: Confidence interval. 
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Figure 1  Multivariate model receiver operating characteristics curve. AUC: 
Area under the curve; CI: Confidence interval.
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sible for such an association. One proposed confounding 
factor is the higher proportion of  women incarcerated for 
drug dealing or drug use[19]. Regarding ethnicity, previous 
studies showed that Caucasians had a higher chance of  
presenting positive for anti-HCV[20,21], but race did not in-
fluence the serological status in our population.
Age over 30 years was independently associated with 
positive serology for HCV, which was also observed in 
other studies[11,16,20]. This finding may be explained by 
a higher risk of  exposure to HCV over the years. Gui-
marães et al[5] found a different result, in which younger 
subjects had a higher chance of  infection, but this find-
ing might represent a local peculiarity.
Self-reported use of  drugs, including ID, has been 
shown to be both valid and reliable[22]. Despite statistical 
significance in univariate analysis, inhaled cocaine did not 
remain in the final model. In the medical literature, HCV 
transmission through sharing materials used for inhaling 
cocaine remain controversial[23]. Use of  ID remained in 
the final model and it was the factor most strongly as-
sociated with positive serology for HCV. This finding 
is consistent with those of  other studies[9-11,20,24-28] and 
supports the effectiveness of  HCV parenteral transmis-
sion. Use of  ID during imprisonment has been reported 
by 3%-28% of  inmates[7]. In the present study, only a 
minority of  IDU (11.6%) referred to injecting inside 
prison. As previously mentioned[10], difficulty in obtain-
ing equipment for use of  ID can lead to sharing, mak-
ing HCV transmission easier. In our population, 32.6% 
declared that they shared needles, so a needle exchange 
program might be effective.
It has been demonstrated that HCV seroprevalence 
was three times higher in prisoners who had tattoos, when 
compared to those who did not[10]. In spite of  observing 
an association between tattoos and HCV in univariate 
analysis, we did not identify an independent effect of  this 
variable in HCV seroprevalence. In accordance with Hel-
lard et al[29], in this study tattoos were strongly associated 
with use of  drugs, presenting multicollinearity issues in 
multivariate analysis. However, it is important to point out 
that tattooing inside prison was not associated with posi-
tive anti-HCV, unlike previous findings[29]. Therefore, this 
might not be an important route of  transmission in the 
studied population.
Other proposed routes of  transmission do not seem 
to be relevant in the studied population. All of  the sub-
jects with positive anti-HCV denied a history of  blood 
transfusion. Sharing personal care items and a history 
of  getting wounded by a sharp weapon in a struggle oc-
curred equally in prisoners in both groups-positive and 
negative anti-HCV.
It has been suggested that previous imprisonment 
would be associated with HCV infection[5]. Despite its 
significance in univariate analysis, this variable was not in-
dependently associated with a positive serology for HCV. 
Subjects with previous imprisonment, when compared to 
those without this background, had a higher proportion 
of  IDU, and for this reason would present higher HCV 
seroprevalence. For IDU, imprisonment is a fairly com-
mon event, due to the illegality of  their behavior or to 
crimes committed because of  the high cost of  drugs on 
the black market[30].
Sexual transmission of  HCV is controversial[10]. Some 
authors consider this route of  transmission ineffective[31,32], 
which is corroborated by the fact that use of  condoms did 
not seem to protect the studied prisoners from HCV infec-
tion. An association between HCV and syphilis has been 
described[5,33,34] and we observed that a history of  previous 
syphilis was independently associated with positive serol-
ogy for HCV, even after adjustment for ID use and other 
confounding factors. Syphilis may be a marker of  sexual 
promiscuity, but variables that evaluate this aspect, such as 
number of  partners in the last year, other previous STD 
and having already paid or been paid for sex, were not as-
sociated with HCV infection. We suggest that HCV is not 
associated with STD in general, but with genital ulcers, 
inherent in syphilitic infection. As previously suggested[35], 
blood containing HCV would penetrate more effectively 
through injured genital skin. Other studies corroborate the 
hypothesis of  genital ulcers influencing HCV transmis-
sion[23,35]. Therefore, in spite of  not being the main route, 
sexual transmission seems to have a role in this population.
Some studies[25,35] stated that homosexuality would lead 
to a higher chance of  HCV infection. This association 
was not confirmed in our study. All the subjects with posi-
tive anti-HCV denied homosexual practices. This finding 
demonstrates that perhaps the association found in other 
studies might be related to risk behaviors, instead of  ho-
mosexuality itself, which is in accordance with Fox et al[26] 
and Mahfoud et al[15].
A previous partner infected by HCV and household 
contact with an HCV carrier were associated with posi-
tive serology for HCV. However, only household contact 
with an infected subject was retained in the final model. 
One possible explanation would be that, although both 
groups referred equally to sharing personal care items, 
household contact may lead to blood to blood contact 
by common use of  such objects sporadically or in an un-
observed manner.
Most HCV infections are acquired before imprison-
ment[10,36], but transmission inside prisons has been re-
ported[22,37], which justifies implementation of  prevention 
programs, especially in populations with a high propor-
tion of  susceptible subjects, such as the one in this study.
Our study has some limitations. This research included 
populations from two institutions, which makes external 
validity difficult for other populations in the world or even 
in other institutions in Northeastern Brazil. Some prisoners 
may not have answered some questions correctly, especially 
the ones concerning STD, chronological aspects and with 
legal implications, such as the use of  ID inside prison. 
Strengths of  the study include: a short period of  data col-
lection, showing the real HCV prevalence at that moment; 
interviews were conducted before test results were avail-
able, minimal ascertainment bias; and high sensitivity of  
the rapid test used, which avoids underestimation of  HCV 
seroprevalence. It has been described that this test has both 
sensitivity and specificity close to 100%[38,39].
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The data shown corroborate the hypothesis that, in 
the studied prisoners, parenteral HCV transmission is 
the main route. However, there is evidence to suggest a 
role for sex and household contact in HCV transmission. 
This study demonstrated low HCV seroprevalence, with 
a high proportion of  subjects having genotype 1. The 
large number of  susceptible individuals in the studied 
population, the poor response of  genotype 1 to antiviral 
treatment and the progress of  chronic infection make 
prevention programs more important. It has been shown 
that treatment is cost-effective[40], even in an imprisoned 
population[41]. Entering the prison system could be an 
opportunity to treat and break the transmission cycle. In 
addition, treatment adherence and side effects could be 
closely monitored.
Data on hepatitis C in Brazil are still scarce, so more 
epidemiological studies are necessary in order to guide 
and monitor prevention programs. We defend the offer 
of  anti-HCV tests for those with a higher chance of  in-
fection, such as those with a previous history of  syphilis, 
those aged over 30 years, IDU, or those who had lived 
with an HCV carrier, to improve the positive predictive 
value of  the tests. This active research should be guided, 
if  possible, by local studies. Even the ones not eligible for 
treatment may reduce transmission and progress to end-
stage liver disease after receiving counseling. 
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